Clinical trials
Colorectal Cancer (MSI-H) clinical trials
Below are recruiting colorectal cancer (msi-h) clinical trials, each written for real people, not researchers. We’re tracking 98 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT06763029RecruitingPhase 2
Study of three drugs for advanced colorectal cancer after first treatment
This trial tests a combination of three drugs (irinotecan liposomes, cetuximab, and vemurafenib) for people with advanced colorectal cancer that has a specific genetic change (BRAF V600E mutation) and did not respond to first treatment. The goal is to see if this combination can help shrink tumors or slow the cancer's growth.
Shanghai, Shanghai MunicipalityAges 18–80 - NCT06878131Recruiting
Precision-MRD: Targeted therapy study for colorectal cancer with MRD
This study looks at how well targeted therapies work for people with colorectal cancer who have minimal residual disease (MRD, tiny amounts of cancer left after treatment) detected by a blood test. It is for people who have a specific genetic change (biomarker) in their tumor and have not been treated with the targeted therapy for that biomarker before.
Houston, TexasAges 18 years+ - NCT06903858RecruitingPhase 2
Toripalimab plus celecoxib for dMMR/MSI-H colorectal cancer
This trial tests whether combining toripalimab (an immunotherapy) with celecoxib (an anti-inflammatory drug) can shrink locally advanced colorectal tumors that have specific genetic features (dMMR or MSI-H). It aims to help people who haven't had any prior treatment for their colorectal cancer.
Guangzhou, GuangdongAges 18 years+ - NCT06959550RecruitingPhase 2
Ivonescimab for previously treated metastatic colorectal cancer
This trial tests a new drug called ivonescimab, which is a bispecific antibody that targets both PD-1 and VEGF. It is for people with metastatic colorectal cancer who have already tried standard treatments and may or may not have received immunotherapy before, depending on their tumor type.
Houston, TexasAges 18 years+ - NCT07011576RecruitingPhase 2
Fruquintinib plus FOLFIRI for second-line metastatic colorectal cancer
This trial tests a combination of two drugs, fruquintinib and FOLFIRI chemotherapy, as a second treatment option for people with metastatic colorectal cancer. It is designed for patients who have already received one prior treatment containing oxaliplatin, fluoropyrimidine, and bevacizumab.
Denver, ColoradoAges 18 years+ - NCT07076823RecruitingPhase 1
Canagliflozin for MSI-H colorectal cancer
This trial tests a diabetes drug, canagliflozin, for people with a specific type of colorectal cancer (MSI-H). It's for those whose cancer has continued to grow after at least two standard treatments.
Chengdu, SichuanAges 18–80 - NCT07213570RecruitingPhase 2
Second-line regorafenib for advanced RAS-mutant colorectal cancer
This trial tests regorafenib as a second-line treatment for people with advanced colorectal cancer that has a RAS mutation. It aims to see if this targeted therapy can help when the first treatment stopped working.
Naples, ItalyAges 18 years+ - NCT07262619RecruitingPhase 1/Phase 2
Study of EIK1005 for advanced solid tumors
This study tests an experimental drug called EIK1005, either alone or combined with another drug (pembrolizumab), for people with advanced solid tumors, especially those with MSI-H or dMMR cancers (tumors that have trouble repairing their DNA). The goal is to see if it can shrink tumors or slow cancer growth.
Morristown, New JerseyAges 18 years+ - NCT07353645RecruitingPhase 1/Phase 2
KRAS vaccine for colorectal and pancreatic cancer after surgery
This trial tests a new vaccine that targets KRAS mutations in patients with colorectal or pancreatic cancer after surgery and chemotherapy. The goal is to see if the vaccine can help prevent the cancer from coming back.
Nanjing, JiangsuAges 18–75 - NCT07405476RecruitingPhase 2
Zanidatamab before surgery for HER2 positive colon or rectal cancer
This trial tests if the drug zanidatamab, given before surgery, can help treat colon or rectal cancer that has a specific marker called HER2. The goal is to see if this approach can shrink tumors and improve outcomes for people whose cancer has not spread to other parts of the body.
Atlanta, GeorgiaAges 18 years+ - NCT07327489Recruiting
Live tumor biopsy study to predict immunotherapy response
This trial studies how well immunotherapy might work by analyzing fresh tumor biopsies. It may help predict which treatments are best for your cancer.
Fort Smith, ArkansasAges 18 years+ - NCT07644286RecruitingPhase 2
Pirfenidone and immunotherapy with optional radiation for advanced colorectal cancer
This study tests a combination of three treatments—pirfenidone (an anti-scarring drug), a PD-1 inhibitor (an immunotherapy that helps your immune system fight cancer), and sometimes radiation—for colorectal cancer that has stopped responding to standard treatments. The goal is to see if this combination can slow or shrink your cancer.
Wuhan, HubeiAges 18–75 - NCT06936527Enrolling by invitationPhase 1/Phase 2
Combination therapy for metastatic colorectal cancer with RAS mutation
This trial tests a new drug called XS-03 combined with standard chemotherapy and bevacizumab for people with metastatic colorectal cancer that has a specific genetic change called a RAS mutation. It aims to see if this combination is more effective than current treatments.
BeijingAges 18–70 - NCT07333053Recruiting
Chemotherapy through a catheter for advanced colorectal cancer
This trial tests giving chemotherapy directly into the artery that feeds the tumor, which may help control advanced colorectal cancer that cannot be removed with surgery. It is for people who have not yet had other treatments and whose main tumor is in the colon or rectum.
Xicheng, Beijing MunicipalityAges 18 years+ - NCT07284849RecruitingPhase 3
Testing a new drug combo for advanced colorectal cancer
This trial tests whether adding an experimental drug (INCA33890) to standard chemotherapy and bevacizumab helps people with a certain type of advanced colorectal cancer. It is for those whose cancer has spread and has not been treated yet with systemic therapy.
Mobile, AlabamaAges 18 years+ - NCT07228832RecruitingPhase 3
Study of two drugs with chemo for advanced colorectal cancer
This clinical trial tests a new drug, ivonescimab, against an approved drug, bevacizumab. Both are given with standard chemotherapy (FOLFOX) for people with advanced colorectal cancer that has not been treated yet with chemo or other drugs.
Mobile, AlabamaAges 18 years+ - NCT07133750RecruitingPhase 2
PM8002 plus chemo for untreated metastatic colorectal cancer
This trial tests a new combination therapy (PM8002 plus chemotherapy) for people with metastatic colorectal cancer who have not had prior treatment. It may be an option if your cancer is not MSI-H/dMMR and you are in good overall health.
Beijing, Beijing MunicipalityAges 18 years+ - NCT05462236RecruitingPhase 2
Study drug AUM001 with immunotherapy or chemotherapy for metastatic colon cancer
This Phase 2 trial tests AUM001 (a targeted drug) combined with either pembrolizumab (an immunotherapy) or irinotecan (a chemotherapy) in people with metastatic colorectal cancer. It aims to shrink tumors and improve outcomes when standard treatments have already been tried.
Camperdown, New South WalesAges 18 years+ - NCT06243393RecruitingPhase 2/Phase 3
Sacituzumab govitecan for advanced colorectal cancer
This study tests a drug called sacituzumab govitecan for people with metastatic colorectal cancer who have already tried several standard treatments. It may be an option if your cancer is not MSI-H or dMMR and you haven't had irinotecan recently.
Heidelberg, Baden-WurttembergAges 18 years+ - NCT06425133RecruitingPhase 2
Regorafenib plus low-dose chemo for advanced colorectal cancer
This trial tests a combination of regorafenib (a targeted pill that cuts off blood supply to tumors) with a low-dose, continuous chemotherapy regimen for people whose colorectal cancer has spread and is no longer responding to standard treatments. The goal is to see if this mix can slow or stop the cancer's growth.
AuxerreAges 18 years+ - NCT06980532RecruitingPhase 1/Phase 2
Glumetinib and Fruquintinib for advanced colorectal cancer
This trial tests a combination of two targeted drugs (Glumetinib and Fruquintinib) for people with a specific type of advanced colorectal cancer that has a change in the MET gene (amplification) or too much MET protein. It is for those whose cancer has not responded to at least two prior treatments.
Wuhan, HubeiAges 18 years+ - NCT07042685RecruitingPhase 2
5-FU and Fruquintinib for advanced colorectal cancer
This trial tests a combination of two drugs (5-FU and fruquintinib) in people with advanced colorectal cancer that cannot be removed by surgery or has spread. It is for those who have not had chemotherapy before.
Houston, TexasAges 18 years+ - NCT07309289RecruitingPhase 3
Comparing two drug combos for first-line metastatic colorectal cancer
This trial tests whether a combination of chemotherapy drugs (NALIRIFOX) plus targeted therapy works better than another standard combination (FOLFOX) plus targeted therapy for people with metastatic colorectal cancer who haven't had treatment yet. It aims to find a more effective first treatment option.
ShanghaiAges 18 years+ - NCT07079631RecruitingPhase 1/Phase 2
Testing BNT314 with pumitamig and chemo for advanced colorectal cancer
This trial tests a new combination of drugs (BNT314 and pumitamig) plus chemotherapy for people with advanced colorectal cancer that has not responded to prior treatments. The goal is to see if this combination is safe and helps shrink or control the cancer.
New Haven, ConnecticutAges 18 years+
Hear when a new Colorectal Cancer (MSI-H) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for colorectal cancer (msi-h)?
- Yes. Clin2 currently lists 98 recruiting colorectal cancer (msi-h) studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a colorectal cancer (msi-h) trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a colorectal cancer (msi-h) trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.